dehydroepiandrosterone has been researched along with Multiple Sclerosis, Relapsing-Remitting in 3 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experimental allergic encephalomyelitis (EAE), a Th1 polarized demyelinating disease of the central nervous system (CNS), shares many pathological and clinical similarities with multiple sclerosis (MS), and thus represents an attractive animal model for this disease." | 1.31 | A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. ( Auci, DL; Drought, H; Matejuk, A; Morgan, EE; Offner, H; Reading, CL; Vandenbark, AA; Zamora, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orefice, N | 1 |
| Carotenuto, A | 1 |
| Mangone, G | 1 |
| Bues, B | 1 |
| Rehm, R | 1 |
| Cerillo, I | 1 |
| Saccà, F | 1 |
| Calignano, A | 1 |
| Orefice, G | 1 |
| Offner, H | 1 |
| Zamora, A | 1 |
| Drought, H | 1 |
| Matejuk, A | 1 |
| Auci, DL | 1 |
| Morgan, EE | 1 |
| Vandenbark, AA | 1 |
| Reading, CL | 1 |
| Kümpfel, T | 1 |
| Then Bergh, F | 1 |
| Friess, E | 1 |
| Uhr, M | 1 |
| Yassouridis, A | 1 |
| Trenkwalder, C | 1 |
| Holsboer, F | 1 |
3 other studies available for dehydroepiandrosterone and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis.
Topics: Adult; Biomarkers; Brain; Dehydroepiandrosterone; Female; Humans; Male; Middle Aged; Multiple Sclero | 2016 |
A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE.
Topics: Androstenes; Androstenols; Animals; CD4-Positive T-Lymphocytes; Cell Division; Dehydroepiandrosteron | 2002 |
Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis.
Topics: Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Dehydroepiandrosterone; Dexamet | 1999 |